Trials / Completed
CompletedNCT00368134
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Compare the Effects of 12 Weeks Treatment With Vildagliptin 50 mg Bid to Voglibose 0.2 mg Tid in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 370 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
This study is designed to evaluate the efficacy, safety and tolerability of vildagliptin compared to voglibose in patients with type 2 diabetes. Please note this study is not being conducted in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin |
Timeline
- Start date
- 2006-08-01
- First posted
- 2006-08-24
- Last updated
- 2007-06-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00368134. Inclusion in this directory is not an endorsement.